Your browser doesn't support javascript.
loading
Microvascular Loss and Diastolic Dysfunction in Severe Symptomatic Cardiac Allograft Vasculopathy.
Daud, Anees; Xu, David; Revelo, Monica P; Shah, Zubair; Drakos, Stavros G; Dranow, Elizabeth; Stoddard, Gregory; Kfoury, Abdallah G; Hammond, M Elizabeth H; Nativi-Nicolau, Jose; Alharethi, Rami; Miller, Dylan V; Gilbert, Edward M; Wever-Pinzon, Omar; McKellar, Stephen H; Afshar, Kia; Khan, Farman; Fang, James C; Selzman, Craig H; Stehlik, Josef.
Afiliação
  • Daud A; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Xu D; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Revelo MP; Department of Pathology (M.P.R., M.E.H.H.,D.V.M.).
  • Shah Z; Utah Transplant Affiliated Hospitals Cardiac Transplant Program, Salt Lake City (M.P.R., S.G.D., A.G.K., M.E.H.H., J.N.-N., R.A., D.V.M.,E.M.G., O.W.-P., S.H.M., K.A., F.K., J.C.F., C.H.S., J.S.).
  • Drakos SG; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Dranow E; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Stoddard G; University of Utah School of Medicine, Salt Lake City. George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT (S.G.D., J.N.-N., E.M.G., O.W.-P., J.S.).
  • Kfoury AG; Utah Transplant Affiliated Hospitals Cardiac Transplant Program, Salt Lake City (M.P.R., S.G.D., A.G.K., M.E.H.H., J.N.-N., R.A., D.V.M.,E.M.G., O.W.-P., S.H.M., K.A., F.K., J.C.F., C.H.S., J.S.).
  • Hammond MEH; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Nativi-Nicolau J; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Alharethi R; Intermountain Medical Center Heart Institute, Salt Lake City, UT (M.E.H.H., R.A., D.V.M., K.A., A.G.K.).
  • Miller DV; Department of Pathology (M.P.R., M.E.H.H.,D.V.M.).
  • Gilbert EM; Intermountain Medical Center Heart Institute, Salt Lake City, UT (M.E.H.H., R.A., D.V.M., K.A., A.G.K.).
  • Wever-Pinzon O; Utah Transplant Affiliated Hospitals Cardiac Transplant Program, Salt Lake City (M.P.R., S.G.D., A.G.K., M.E.H.H., J.N.-N., R.A., D.V.M.,E.M.G., O.W.-P., S.H.M., K.A., F.K., J.C.F., C.H.S., J.S.).
  • McKellar SH; Division of Cardiovascular Medicine (A.D., D.X., Z.S., S.G.D., E.D., G.S., J.N.-N., E.M.G., O.W.-P., J.C.F., J.S.).
  • Afshar K; University of Utah School of Medicine, Salt Lake City. George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT (S.G.D., J.N.-N., E.M.G., O.W.-P., J.S.).
  • Khan F; Utah Transplant Affiliated Hospitals Cardiac Transplant Program, Salt Lake City (M.P.R., S.G.D., A.G.K., M.E.H.H., J.N.-N., R.A., D.V.M.,E.M.G., O.W.-P., S.H.M., K.A., F.K., J.C.F., C.H.S., J.S.).
  • Fang JC; Intermountain Medical Center Heart Institute, Salt Lake City, UT (M.E.H.H., R.A., D.V.M., K.A., A.G.K.).
  • Selzman CH; Utah Transplant Affiliated Hospitals Cardiac Transplant Program, Salt Lake City (M.P.R., S.G.D., A.G.K., M.E.H.H., J.N.-N., R.A., D.V.M.,E.M.G., O.W.-P., S.H.M., K.A., F.K., J.C.F., C.H.S., J.S.).
  • Stehlik J; Division of Cardiothoracic Surgery (S.H.M., C.H.S.).
Circ Heart Fail ; 11(8): e004759, 2018 08.
Article em En | MEDLINE | ID: mdl-30354559
ABSTRACT

BACKGROUND:

Cardiac allograft vasculopathy (CAV) remains an important source of mortality after heart transplant. The aim of our study was to identify structural and microvasculature changes in severe CAV. METHODS AND

RESULTS:

The study group included heart transplant recipients with severe CAV who underwent retransplantation (severe CAV, n=20). Control groups included time from transplant matched cardiac transplant recipients without CAV (transplant control, n=20), severe ischemic cardiomyopathy patients requiring left ventricular assist device implantation (ischemic control, n=18), and normal hearts donated for research (donor control, n=10). We collected baseline demographic information, echocardiography data, and performed histopathologic examination of myocardial microvasculature. Echocardiographic features of severe CAV included lack of eccentric remodeling and presence of significant diastolic dysfunction. In contrast, diastolic function was preserved in transplant control subjects. Histopathologic examination showed increased interstitial fibrosis among severe CAV, transplant controls, and ischemic control patients. Compared with transplant controls, severe CAV subjects had reduced capillary density and increased capillary wall thickness ( P<0.05).

CONCLUSIONS:

Our results suggest that the marked diastolic dysfunction and resultant symptoms in patients with severe CAV may be secondary to the loss of microvasculature and remodeling of remaining microvessels rather than a consequence of interstitial fibrosis. The clinical significance and potential therapeutic implications of these unique microvasculature characteristics warrant further investigation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Capilares / Função Ventricular Esquerda / Transplante de Coração / Disfunção Ventricular Esquerda / Remodelação Vascular Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Capilares / Função Ventricular Esquerda / Transplante de Coração / Disfunção Ventricular Esquerda / Remodelação Vascular Idioma: En Ano de publicação: 2018 Tipo de documento: Article